Mustang Bio, Inc. – NASDAQ:MBIO
Mustang Bio stock price today
$1.6
+1.41
+770.04%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 21 minutes
Mustang Bio stock price monthly change
-54.14%
month
Mustang Bio stock price quarterly change
-54.14%
quarter
Mustang Bio stock price yearly change
-86.17%
year
Mustang Bio key metrics
Market Cap | 8.38M |
Enterprise value | N/A |
P/E | -0.4 |
EV/Sales | N/A |
EV/EBITDA | 0.46 |
Price/Sales | N/A |
Price/Book | 0.46 |
PEG ratio | -0.53 |
EPS | -4.62 |
Revenue | N/A |
EBITDA | -36.69M |
Income | -40.1M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeMustang Bio stock price history
Mustang Bio stock forecast
Mustang Bio financial statements
| Jun 2023 | 0 | -16.23M | |
|---|---|---|---|
| Sep 2023 | 0 | -10.05M | |
| Dec 2023 | 2.88M | -8.61M | -298.96% |
| Mar 2024 | 0 | -5.19M |
| 2027 | 55.6M | -8.86M | -15.94% |
|---|
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 29086000 | 15.37M | 52.85% |
|---|---|---|---|
| Sep 2023 | 20567000 | 16.55M | 80.51% |
| Dec 2023 | 17742000 | 17.61M | 99.31% |
| Mar 2024 | 14592000 | 19.53M | 133.87% |
| Jun 2023 | -12.39M | -34K | -30.28M |
|---|---|---|---|
| Sep 2023 | -12.02M | 5.95M | 250K |
| Dec 2023 | -7.25M | -30K | 3.95M |
| Mar 2024 | -5.32M | 0 | 49K |
Mustang Bio alternative data
| Aug 2023 | 113 |
|---|---|
| Sep 2023 | 113 |
| Oct 2023 | 113 |
| Nov 2023 | 113 |
| Dec 2023 | 113 |
| Jan 2024 | 113 |
| Feb 2024 | 113 |
| Mar 2024 | 80 |
| Apr 2024 | 80 |
| May 2024 | 80 |
| Jun 2024 | 80 |
| Jul 2024 | 80 |
Mustang Bio other data
18.73%
-9.98%
of MBIO is owned by hedge funds
68
-10
17.61M
-7.61M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2021 | 165562 | 0 |
| Apr 2021 | 0 | 2423 |
| Jul 2021 | 86206 | 0 |
| Oct 2021 | 65000 | 4450 |
| Dec 2021 | 0 | 4374 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | ACHENBACH BRIAN officer: SVP, Fin. & Corp. Cont.. | COMMON STOCK | 4,374 | $1.83 | $8,004 | ||
Purchase | LITCHMAN MANUEL MD director, officer.. | COMMON STOCK | 65,000 | $2.24 | $145,600 | ||
Sale | ACHENBACH BRIAN officer: SVP, Fin. & Corp. Cont.. | COMMON STOCK | 4,450 | $2.28 | $10,146 | ||
Purchase | LITCHMAN MANUEL MD director, officer.. | COMMON STOCK | 86,206 | $2.91 | $250,859 | ||
Sale | ACHENBACH BRIAN officer: SVP, Fin. & Corp. Cont.. | COMMON STOCK | 2,423 | $3.36 | $8,141 | ||
Purchase | LITCHMAN MANUEL MD director, officer.. | COMMON STOCK | 165,562 | N/A | N/A | ||
Purchase | LITCHMAN MANUEL MD director, officer.. | COMMON STOCK | 100,000 | N/A | N/A | ||
Purchase | ROSENWALD LINDSAY A MD director | COMMON STOCK | 200,000 | N/A | N/A | ||
Purchase | ROSENWALD LINDSAY A MD director | COMMON STOCK | 200,000 | N/A | N/A | ||
Purchase | ROSENWALD LINDSAY A MD director | COMMON STOCK | 200,000 | $1.33 | $266,000 |
| Patent |
|---|
Application COMBINATION THERAPY COMPRISING CANCER-TARGETED CAR-T CELLS AND A METHOD OF USING SAME FOR A TREATMENT FOR CANCER Filling date: 9 Sep 2021 Issue date: 10 Mar 2022 |
Application Filling date: 3 Mar 2021 Issue date: 9 Sep 2021 |
Application Filling date: 27 Nov 2019 Issue date: 16 Jul 2020 |
Application Filling date: 4 Apr 2019 Issue date: 31 Oct 2019 |
| Insider | Compensation |
|---|---|
| Dr. Manuel Litchman (1954) Pres, Chief Executive Officer & Director | $606,870 |
Mr. Brian K. Achenbach M.B.A. (1965) Senior Vice President of Fin. & Corporation Controller | $346,350 |
| Mr. Michael S. Weiss Esq. (1966) Executive Chairman | $60,000 |
-
What's the price of Mustang Bio stock today?
One share of Mustang Bio stock can currently be purchased for approximately $1.6.
-
When is Mustang Bio's next earnings date?
Unfortunately, Mustang Bio's (MBIO) next earnings date is currently unknown.
-
Does Mustang Bio pay dividends?
No, Mustang Bio does not pay dividends.
-
How much money does Mustang Bio make?
Mustang Bio has a market capitalization of 8.38M.
-
What is Mustang Bio's stock symbol?
Mustang Bio, Inc. is traded on the NASDAQ under the ticker symbol "MBIO".
-
What is Mustang Bio's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Mustang Bio?
Shares of Mustang Bio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Mustang Bio's key executives?
Mustang Bio's management team includes the following people:
- Dr. Manuel Litchman Pres, Chief Executive Officer & Director(age: 71, pay: $606,870)
- Mr. Brian K. Achenbach M.B.A. Senior Vice President of Fin. & Corporation Controller(age: 60, pay: $346,350)
- Mr. Michael S. Weiss Esq. Executive Chairman(age: 59, pay: $60,000)
-
How many employees does Mustang Bio have?
As Jul 2024, Mustang Bio employs 80 workers.
-
When Mustang Bio went public?
Mustang Bio, Inc. is publicly traded company for more then 8 years since IPO on 22 Aug 2017.
-
What is Mustang Bio's official website?
The official website for Mustang Bio is mustangbio.com.
-
Where are Mustang Bio's headquarters?
Mustang Bio is headquartered at 377 Plantation Street, Worcester, MA.
-
How can i contact Mustang Bio?
Mustang Bio's mailing address is 377 Plantation Street, Worcester, MA and company can be reached via phone at +7 816524500.
Mustang Bio company profile:
Mustang Bio, Inc.
mustangbio.comExchange:
NASDAQ
Full time employees:
80
Industry:
Biotechnology
Sector:
Healthcare
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.
377 Plantation Street
Worcester, MA 01605
Worcester, MA 01605
CIK: 0001680048
ISIN: US62818Q2030
CUSIP: 62818Q104
